Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Paradigm Kicks Off Genomic Profiling for Cancer Registry

August 5, 2014 2:16 pm | News | Comments

Paradigm has announced they have initiated genomic testing for Pharmatech's AccessPPM Cancer Registry, which is designed to collect EMR data and genomic information to help best match cancer patients with targeted clinical trials. Read more... 

TOPICS:

Scientists Use Subcellular Imaging to Visualize Glutamate Receptors

August 5, 2014 2:08 pm | News | Comments

Scientists at the National Institutes of Health have created high-resolution images of the glutamate receptor, a protein that plays a key role in nerve signaling. The advance, published online in the journal Nature, opens a new window to study protein interactions in cell membranes in exquisite detail. Read more...

TOPICS:

Novimmune to Start Proof of Concept Study for RA Drug

August 5, 2014 11:02 am | News | Comments

Novimmune SA announced the completion of a comprehensive Phase 1 clinical trial investigating the pharmacokinetics, pharmacodynamics, preliminary tolerability and safety of NI-0101, a first-in-class monoclonal antibody against toll-like receptor 4, in presence and absence in vivo of a TLR4 ligand. Read more...

TOPICS:
Advertisement

Parkinson's Drug Eligible for EU Centralized Procedure

August 5, 2014 10:57 am | News | Comments

NeuroDerm Ltd. announced that the European Medicines Agency has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa treatment for advanced Parkinson's disease, eligible for a European Union marketing authorization application procedure ("centralized procedure"). Read more...

TOPICS:

Glioblastoma Triple Therapy Revs Up Immune System

August 5, 2014 10:52 am | News | Comments

A triple therapy for glioblastoma, including two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report by scientists at the Johns Hopkins Kimmel Cancer Center. Read more...

TOPICS:

Muscular Dystrophy Drug Conditionally Approved

August 5, 2014 10:47 am | News | Comments

PTC Therapeutics Inc. announced that the European Commission has granted conditional marketing authorization for Translarna (ataluren), in the European Union for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Read more...

TOPICS:

Global Research Team Advances Insulin Therapy

August 5, 2014 10:41 am | News | Comments

Since its landmark discovery in 1922, insulin has improved the health and extended the lives of more than 500 million people worldwide with diabetes mellitus, yet the question of how this key hormone binds to its target cells in the body’s organs has posed an enduring scientific mystery. Read more...

TOPICS:

US Gov’t, Military Spotted Ebola Drug

August 5, 2014 10:35 am | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

Two American aid workers infected with Ebola are getting an experimental drug so novel it has never been tested for safety in humans and was only identified as a potential treatment earlier this year, thanks to a longstanding research program by the U.S. government and the military. Read more...

TOPICS:
Advertisement

BMS, Allied Minds Form Unique Research Enterprise

August 4, 2014 2:52 pm | News | Comments

Allied Minds and Bristol-Myers Squibb Co. announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the United States. Read more...

TOPICS:

Isis Initiates Phase 3 Infant SMA Study

August 4, 2014 2:40 pm | News | Comments

Isis Pharmaceuticals Inc. announced the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Read more...           

TOPICS:

Jentadueto Gets Label Update with New Trial Info

August 4, 2014 2:27 pm | News | Comments

The U.S. Prescribing Information for Jentadueto tablets now includes clinical trial data that showed linagliptin co-administered with metformin provided statistically significant decreases in blood glucose compared with linagliptin alone. Read more...

TOPICS:

Final Patient Treated in Phase 2 ALS Stem Cell Trial

August 4, 2014 2:06 pm | News | Comments

Neuralstem Inc. announced that the final patient was treated in its Phase 2 trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis, ALS or Lou Gehrig's disease. Read more...       

TOPICS:

Roche to Acquire Santaris Pharma

August 4, 2014 1:52 pm | News | Comments

Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark. Read more...                             

TOPICS:

NIH's Fauci Says Ebola Vaccine Not Far Away

August 4, 2014 1:40 pm | News | Comments

The nation's top infectious disease official says there's hope that a vaccine against Ebola will be available as early as next July. Dr. Anthony Fauci of the National Institutes of Health says such a preventive vaccine has been successfully tested with monkeys. Read more...

TOPICS:

Medivir Licenses RSV Drug Program from BI

August 4, 2014 10:42 am | News | Comments

Medivir AB announced that it has entered a license agreement with Boehringer Ingelheim International GmbH for exclusive, global rights to a drug program for the treatment and prevention of Respiratory Syncytial Virus (RSV) infection. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading